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Abstract
Several studies have demonstrated that systemically administered N-methyl-D-aspartate (NMDA) recep-
tor antagonists increase serotonin (5-HT) and glutamate release in the medial prefrontal cortex (mPFC).
Previously we showed that the perfusion of clozapine in the mPFC prevented the MK-801-induced
increase in extracellular glutamate and 5-HT whereas haloperidol blocked only the eﬀect of MK-801 on
glutamate. To study the contribution of diﬀerent monoaminergic receptors (for which clozapine and
haloperidol exhibit distinct aﬃnities) to these eﬀects, here we used in-vivo microdialysis to examine
the role of local blockade of dopamine D2, 5-HT2A and a1-adrenergic receptors as well as agonism at
dopamine D1 and 5-HT1A receptors in the mPFC on the increased eﬄux of glutamate and 5-HT elicited by
MK-801. The results show that M100907 (5-HT2A antagonist), BAY x 3702 (5-HT1A agonist) and prazosin
(a1-adrenergic antagonist) blocked the MK-801-induced increase of 5-HT and glutamate in the mPFC.
However, raclopride, eticlopride (dopamine D2 antagonists) and SKF-38393 (dopamine D1 agonist) were
able to prevent the increased eﬄux of glutamate (but not that of 5-HT) elicited by MK-801. We propose
that D2 receptor antagonists and D1 agonists would act predominantly on a subpopulation of GABAergic
interneurons of the mPFC, thus leading to an enhanced cortical inhibition that would prevent an excessive
glutamatergic transmission. On the other hand, atypical antipsychotic drugs might further act upon
5-HT2A, 5-HT1A and a1-adrenoceptors present in pyramidal cells (including those projecting to the dorsal
raphe nucleus), which would directly inhibit an excessive excitability of these cells.
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Introduction
Non-competitive N-methyl-D-aspartate (NMDA) re-
ceptor antagonists such as phencyclidine (PCP) and
ketamine have been used as a pharmacological model
of schizophrenia because they can mimic psychotic
and negative symptoms as well as cognitive impair-
ment in healthy individuals (Javitt and Zukin, 1991 ;
Krystal et al., 1994). In rats, NMDA antagonists have
also been shown to increase extracellular glutamate
(Calcagno et al., 2006; Ceglia et al., 2004 ; Lo´pez-Gil
et al., 2007; Lorrain et al., 2003 ; Moghaddam et al.,
1997), dopamine (Adams and Moghaddam, 1998;
Schmidt and Fadayel, 1996), and serotonin (5-HT)
(Adams andMoghaddam, 2001; Amargo´s-Bosch et al.,
2006 ; Calcalgno et al., 2006 ; Ceglia et al., 2004 ; Lo´pez-
Gil et al., 2007 ; Millan et al., 1999) in the medial
prefrontal cortex (mPFC). It has been proposed
that non-competitive NMDA receptor antagonists
might impair GABAergic inhibition of glutamatergic
neurons in the mPFC (Homayoun and Moghaddam,
2007b; Krystal et al., 2003 ; Moghaddam et al., 1997),
leading to downstream changes in other transmitters.
Indeed, GABAergic interneurons in limbic cortex and
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hippocampus are more sensitive to the action of
NMDA receptor antagonists than pyramidal neurons
(Grunze et al., 1996).
Numerous studies have demonstrated that dop-
amine, 5-HT and glutamate play an important role in
schizophrenia and that receptors for these transmitters
are involved in the action of antipsychotic drugs. It
is generally accepted that all available antipsychotic
drugs posses some degree of dopamine D2 receptor
antagonism and that blockade of limbic D2 receptors
improves positive symptoms (Kapur et al., 2000).
However, this has been challenged recently by the
ﬁnding that drugs that attenuate glutamate release
without acting directly on dopamine receptors are
beneﬁcial for positive and negative symptoms (Patil
et al., 2007). With regard to clozapine, the prototypical
atypical antipsychotic drug, it has been suggested that
its superior eﬃcacy and tolerability is partly due to its
lower occupancy of D2 receptors (Kapur et al., 1999)
together with an additional interaction with 5-HT2A
and dopamine D1 receptors (Lundberg et al., 1996).
Therefore, it has been proposed that a weak D2 recep-
tor blockade coupled to a relatively stronger 5-HT2A
inhibition is the key feature of atypical antipsychotic
drugs (see Meltzer, 2004 for review), responsible
for causing fewer extrapyramidal side-eﬀects (EPS).
On the other hand, the relationship found between
cognitive/negative symptoms in schizophrenia and a
reduction of prefrontal dopamine D1 receptor binding
(Okubo et al., 1997) prompted some investigators to
suggest that dopamine D1 receptor agonists might be
helpful in alleviating negative symptoms and cogni-
tive deﬁcits of schizophrenia (seeGoldman-Rakic et al.,
2004 for review). There is also evidence underpinning
the importance of 5-HT1A receptors in certain aspects
of the pharmacotherapy of schizophrenia (Millan,
2000 ; Sumiyoshi et al., 2001). Furthermore, 5-HT1A
receptor agonists reduce the incidence of EPS in
schizophrenia patients treated with haloperidol (Goﬀ
et al., 1991 ; Moss et al., 1993). Finally, many clinically
eﬀective antipsychotic drugs (both classical and
atypical) exhibit a1-adrenoceptor antagonism (Arnt
and Skarsfeldt, 1998 ; Bymaster et al., 1996), which
has been postulated to be involved in their clinical
action (Svensson, 2003). However, although central
a1-adrenoceptors may regulate sensorimotor gating
altered in schizophrenia (Alsene et al., 2006), there are
not studies dealing with the occupancy of a1-adreno-
ceptors in individuals under antipsychotic treatment.
In the preclinical setting, it has been shown that the
local administration of antipsychotic drugs decrease
extracellular 5-HT in the mPFC (Amargo´s-Bosch
et al., 2003, 2007). Activation of 5-HT1A receptors and
blockade of 5-HT2A receptors might contribute to this
eﬀect since both types of compounds were able to
prevent the increases in 5-HT and glutamate, as well
as cognitive deﬁcits induced by NMDA receptor
antagonists (Calcagno et al., 2006 ; Carli et al., 2006;
Ceglia et al., 2004). Furthermore, clozapine and halo-
peridol attenuated PCP-induced increase in cortical
glutamate (Abekawa et al., 2006) as well as the
elevated ﬁring of a population of mPFC pyramidal
neurons elicited by PCP or MK-801 (Homayoun
and Moghaddam, 2007a; Kargieman et al., 2007).
Interestingly, clozapine exhibited a levelling eﬀect on
the ﬁring of pyramidal cells in the mPFC (Homayoun
and Moghaddam, 2007a). This ﬁne-tuning eﬀect might
contribute to the unique therapeutic eﬃcacy of cloza-
pine in schizophrenia.
In a previous study we showed that the perfusion
of clozapine in the mPFC prevented the MK-801-
induced increase in extracellular glutamate and 5-HT
whereas haloperidol blocked only the eﬀect of MK-801
on glutamate (Lo´pez-Gil et al., 2007). To study the
contribution of diﬀerent monoaminergic receptors
(for which clozapine and haloperidol exhibit distinct
aﬃnities) to these eﬀects, in the present study we
examined the role of blockade of dopamine D2, 5-HT2A
and a1-adrenergic receptors as well as agonism at
dopamine D1 and 5-HT1A receptors in the mPFC on the




Male Wistar rats (Charles River Laboratories,
Cerdanyola del Valle`s, Spain) weighing 250–280 g
were used. They were maintained on a 12 h light/dark
cycle (lights on 07:00) and housed three per cage
before surgery and individually after surgery. Food
and water were available ad libitum. All experimental
procedures followed European Union regulations
(Oﬃcial Journal of the European Communities
L358/1, 18 December 1986), and were approved by
the Institutional Animal Care and Use Committees.
To reduce the inﬂuence of between-day variations
on drug eﬀects, most experimental groups were not
completed at once, but throughout the duration of the
whole work instead.
Drugs and reagents
All the HPLC reagents were of analytical grade
and obtained from Merck (Darmstadt, Germany).
Dizocilpine maleate (MK-801), 5-hydroxytryptamine
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oxalate, glutamate, and ready-made o-phthaldialde-
hyde (OPA) reagent, made up of 1 mg OPA per ml
solution with 2-mercaptoethanol as the sulphydryl
moiety, were purchased from Sigma-Aldrich (Tres
Cantos, Spain). Raclopride, eticlopride hydrochloride,
prazosin hydrochloride, and SKF-38393 were from
Tocris (Bristol, UK). Citalopram hydrobromide, BAY x
3707, and M100907 (formerly MDL-100907) were gen-
erously donated by H. Lundbeck A/S (Copenhagen-
Valby, Denmark), Bayer AG (Wuppertal, Germany)
and Pierre-Fabre (Castres, France), respectively.
MK-801 was dissolved in saline for intraperitoneal
(i.p.) administration. The dose of MK-801 was taken
from our previous study (Lo´pez-Gil et al., 2007). It is
possible that lower doses of MK-801 are suﬃcient
to induce stereotypies and increases in pyramidal cell
ﬁring (Jackson et al., 2004), but they failed to induced
changes in extracellular glutamate (Lo´pez-Gil et al.,
2007). All other drugs were dissolved in the perfusion
ﬂuid for local application through dialysis probes.
Concentrated solutions (1 mM) were stored at x80 xC
and working solutions were prepared immediately
before the experiments by dilution in the perfusion
ﬂuid. Concentrations are expressed as free bases.
Because of the diﬃculty in obtaining the real extra-
cellular concentration of the drugs perfused through
the dialysis ﬂuid, we tested the least eﬀective con-
centrations (i.e. within the low micromolar range) in
order to gain selectivity for the speciﬁc receptors
studied.
Microdialysis procedures
Concentric microdialysis probes were constructed
with a 4-mm-long membrane. Following anaesthesia
with sodium pentobarbital (60 mg/kg i.p.), rats were
placed in a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA), and dialysis probes were
implanted in the mPFC and secured to the skull with
anchor screws and dental cement. Stereotaxic co-
ordinates from Bregma and skull surface were:
AP+3.2 mm, Lx0.8 mm, DVx6.0 mm; according to
Paxinos andWatson (1986). Microdialysis experiments
were conducted 20–24 h after surgery in freely moving
rats by continuously perfusing probes with a ﬂuid
containing 125 mM NaCl, 2.5 mM KCl, 1.26 mM CaCl2,
1.18 mMMgCl2, and 1 mM citalopram. The addition of a
5-HT uptake blocker to the perfusion ﬂuid is used in
some microdialysis experiments to reduce clearance
from the extracellular space, thus enhancing the
release component of extracellular 5-HT (Adell et al.,
2002). On the other hand, low concentrations of 5-HT
uptake blockers, such as used in the present study,
are without eﬀect on dialysate glutamate in vivo
(Langman et al., 2006 ; C. M. T. Queiroz and F. Artigas,
unpublished results). Furthermore, voltammetric stud-
ies have shown that MK-801 may interact with the
serotonin transporter (Callado et al., 2000 ; Iravani
et al., 1999), thereby underscoring the importance of
including citalopram in the perfusion ﬂuid.
The artiﬁcial cerebrospinal ﬂuid was perfused
at 1.5 ml/min with a Harvard model 22 syringe
pump (Harvard Apparatus, South Natick, MA,
USA) attached to an overhead liquid swivel (Instech,
Plymouth Meeting, PA, USA). Dialysate samples of
30 ml were collected every 20 min and divided into
two fractions for the determination of 5-HT (20 ml)
and glutamate (10 ml). The in-vitro dialysis probe re-
coveries for 5-HT and glutamate were 16% and 17%,
respectively. Owing to the incidental occurrence of
chromatographic problems, for some rats data on only
one transmitter (glutamate or 5-HT) were available.
After an initial 1 h sample of dialysate was discarded,
four samples were collected to establish stable baseline
levels of 5-HT and glutamate (expressed as concen-
tration of transmitter in a 30-ml sample) before
any pharmacological treatment. At the completion of
dialysis experiments, rats were given an overdose of
sodium pentobarbital and a Fast Green solution
was perfused through the dialysis probes to stain
the surrounding tissue for subsequent histological
examination.
Biochemical determinations
The concentration of 5-HT in dialysate samples
was determined by an HPLC system consisting of a
Waters 717plus autosampler (Waters Cromatograﬁa,
Cerdanyola, Spain), a Hewlett-Packard series 1050
pump (Agilent Technologies, Las Rozas, Spain),
a 3m octadecylsilica (ODS) column (7.5 cmr0.46 cm;
Beckman, San Ramon, CA, USA), and an ampero-
metric detector Hewlett-Packard 1049 (Agilent Tech-
nologies) set at an oxidation potential of 0.6 V. The
mobile phase consisted of 0.15 M NaH2PO4, 1.8 mM
octyl sodium sulfate, 0.2 mM EDTA (pH 2.8, adjusted
with phosphoric acid), and 30% methanol, and was
pumped at 0.7 ml/min (Lo´pez-Gil et al., 2007). For the
determination of glutamate, another HPLC system
was used, which consisted of a Waters 717plus auto-
sampler, a Waters 600 quaternary gradient pump, and
a Nucleosil 5m ODS column (10 cmr0.4 cm; Tekno-
kroma, Spain). Dialysate samples were precolumn-
derivatized with OPA reagent and the entire process
was carried out by the autosampler. Brieﬂy, 90 ml dis-
tilled water was added to the 10 ml dialysate sample
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and this was followed by the addition of 15 ml
OPA reagent. After 2.5 min reaction, 80 ml of this
mixture was injected into the column. Detection was
carried out with a Waters 470 scanning ﬂuorescence
detector using excitation and emission wavelengths of
360 nm and 450 nm, respectively. The mobile phase
was pumped at 0.8 ml/min and consisted of two
components (Calcagno et al., 2006) : solution A, made
up of 0.05 m Na2HPO4, 28% methanol, adjusted to
pH 6.4 with 85% H3PO4, and solution B, made up of
100% methanol/H2O (8:2 ratio). After the elution of
glutamate peak at 3 min with 100% solution A, a
gradient was established going from 100% solution A
to 100% solution B in 2 min. After washing out late-
eluting peaks (3 min), mobile phase returned to
initial conditions (100% solution A) in 2 min. The
detection limits for 5-HT and glutamate were 4 fmol
and 0.2 pmol, respectively (signal-to-noise ratio 3).
Quantiﬁcation of 5-HT and glutamate was carried out
by comparison to a daily standard curve compris-
ing the concentrations of transmitters expected in
dialysate samples.
Statistics
Data (mean¡S.E.M.) are expressed as fmol/30 ml for
5-HT and pmol/30 ml for glutamate, and shown in the
ﬁgures as percentages of basal values, averaged from
four fractions collected before treatment. The changes
in dialysate 5-HT and glutamate for each drug were
analysed by two-way repeated-measures analysis
of variance (ANOVA) with time and treatment as
factors. When signiﬁcant eﬀects were found, post-hoc
Newman–Keuls (NK) multiple comparison tests were
used to compare eﬀects of diﬀerent treatment groups.
The level of signiﬁcance was set at p<0.05.
Results
The basal (pre-drug) concentrations of 5-HT and
glutamate in dialysate samples of the mPFC, not cor-
rected for in-vitro recovery, were 49.8¡1.4 fmol/30 ml
(n=168) and 28.3¡3.7 pmol/30 ml (n=168), respect-
ively. Although the basal concentration of glutamate is
higher than that in our previous study (Lo´pez-Gil
et al., 2007), it falls within the range reported by
other authors (Adams and Moghaddam, 2001; Lorrain
et al., 2003 ; Moghaddam et al., 1997). The systemic
administration of MK-801 to rats increased the extra-
cellular concentration of 5-HT in comparison to the
saline-injected group, as demonstrated by the signiﬁ-
cant eﬀect of treatment (F1,13=33.91, p<0.0001), time
(F15,195=7.99, p<0.00001), and treatmentrtime inter-
action (F15,195=8.65, p<0.00001). MK-801 also elevated
extracellular glutamate in the mPFC as shown by the
signiﬁcant eﬀect of treatment (F1,13=31.12, p<0.0001),
time (F15,195=7.18, p<0.00001), and treatmentrtime
interaction (F15,195=7.16, p<0.00001).
Eﬀects of dopamine D2 antagonists
Two diﬀerent D2-like antagonists were used, raclo-
pride and eticlopride, which possesses 10-fold greater
aﬃnity than raclopride for dopamine D2/D3 receptors
(Assie´ et al., 2006). Raclopride, which by itself had
no eﬀect on 5-HT and glutamate in saline-injected
animals, was unable to block the MK-801-induced
increase in dialysate 5-HT (Figure 1a). However,
it prevented the eﬀect of MK-801 on glutamate
(F3,21=12.08, p<0.0001; Figure 1b) in a concentration-
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Figure 1. Eﬀects of the intra-medial prefrontal cortex (mPFC)
perfusion (line at foot of panels) of raclopride (Rac) (10 and
30 mM; Rac 10 and Rac 30, respectively) on the eﬄux of
(a) 5-HT and (b) glutamate in the mPFC elicited by MK-801
(1 mg/kg i.p., arrow). Data (mean¡S.E.M.) are expressed
as percentage changes of the four basal pre-drug values.
Number of animals given in parentheses. The control group
received an injection of saline (1 ml/kg i.p.). Groups given
saline and MK-801 are the same in all ﬁgures and are
depicted as dotted lines.
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that only the concentration of 30 mM raclopride sig-
niﬁcantly abolished the increase in cortical glutamate
elicited by MK-801 (p<0.002, NK test). At 100 mM,
raclopride was also unable to block the MK-801-
induced increase in cortical 5-HT (data not shown).
In a similar way, eticlopride did not alter basal
levels of 5-HT and glutamate when perfused in saline-
injected animals and failed to reduce the eﬀects of
MK-801 on cortical 5-HT (Figure 2a). It blocked
only the eﬀects of MK-801 on glutamate (F15,315=5.22,
p<0.00001 ; Figure 2b). Both concentrations of eticlo-
pride were equally eﬀective in this respect (p<0.0005,
NK test).
Eﬀects of 5-HT2A antagonists and 5-HT1A agonists
In contrast to dopamine D2 antagonists, the selective
5-HT2A antagonist, M100907, prevented the increase in
5-HT (F3,20=15.08, p<0.0001; Figure 3a) and gluta-
mate (F3,20=15.72, p<0.00002; Figure 3b) elicited by
MK-801. Post-hoc comparisons showed that both
concentrations of M100907 had similar eﬀects on
5-HT (p<0.02, NK test) and glutamate (p<0.0005;
Newman-Keuls test). When administered to saline-
injected animals, M100907 did not change the basal
extracellular concentration of 5-HT, but a signiﬁcant
increase in cortical glutamate was observed (F2,14=
10.67, p<0.002) although this was only statistically
signiﬁcant after the perfusion of 10 mM M100907
(p<0.003, NK test).
The selective 5-HT1A agonist, BAY x 3702, also
abolished the increase in 5-HT (F3.21=12.92, p<0.0001;
Figure 4a) and glutamate (F3,19=20.30, p<0.00001;
Figure 4b) elicited by MK-801. Post-hoc comparisons
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Figure 2. Eﬀects of the intra-medial prefrontal cortex (mPFC)
perfusion (line at foot of panels) of eticlopride (Eti) (0.1 and
1 mM; Eti 0.1 and Eti 1, respectively) on the eﬄux of (a) 5-HT
and (b) glutamate in the mPFC elicited by MK-801 (1 mg/kg
i.p., arrow). Data (mean¡S.E.M.) are expressed as percentage
changes of the four basal pre-drug values. Number of animals
given in parentheses. The control group received an injection
of saline (1 ml/kg i.p.). Groups given saline and MK-801 are
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Figure 3. Eﬀects of the intra-medial prefrontal cortex (mPFC)
perfusion (line at foot of panels) of M100907 (M100) (1 and
10 mM; M100 1 and M100 10, respectively) on the eﬄux of
(a) 5-HT and (b) glutamate in the mPFC elicited by MK-801
(1 mg/kg i.p., arrow). Data (mean¡S.E.M.) are expressed
as percentage changes of the four basal pre-drug values.
Number of animals given in parentheses. The control group
received an injection of saline (1 ml/kg i.p.). Groups given
saline and MK-801 are the same in all ﬁgures and are
depicted as dotted lines.
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comparable eﬀects on 5-HT (p<0.002, NK test) and
glutamate (p<0.0005, NK test). Although it seemed
that the concentration of 1 mM BAY x 3702 was more
eﬀective than that of 30 mM in blocking the MK-801-
induced increase of 5-HT (Figure 4a), this diﬀerence
was not statistically signiﬁcant. When applied alone in
saline-injected animals, BAY x 3702 failed to change
the concentration of glutamate, but reduced that of
5-HT (F2,15=8.24, p<0.005; Figure 4a). Post-hoc com-
parisons showed that both concentrations of BAY x
3702 were equally eﬀective (p<0.02, NK test).
Eﬀects of a1-adrenergic antagonists
Similar to 5-HT2A antagonists and 5-HT1A agonists, the
intra-mPFC perfusion of the selective a1-adrenergic
antagonist, prazosin, blocked the increases in 5-HT
(F3,19=10.38, p<0.003; Figure 5a) and glutamate
(F3,20=11.44, p<0.001 ; Figure 5b) evoked by MK-801,
in a concentration-dependent manner. Post-hoc com-
parisons showed that only 10 mM prazosin was re-
quired to prevent the MK-801-induced increases in
5-HT (p<0.02, NK test) and glutamate (p<0.005, NK
test). When applied alone in saline-injected animals,
prazosin did not alter the concentration of glutamate,
but reduced that of 5-HT (F2,13=5.69, p<0.02 ;
Figure 5a). Post-hoc comparisons showed that only the
concentration of 10 mM prazosin reduced basal 5-HT
levels in the mPFC (p<0.02, NK test).
Eﬀects of dopamine D1 agonists
SKF-38393 has similar aﬃnity for dopamine D1 and
D5 receptors. Like dopamine D2 antagonists, the
dopamine D1 agonist, SKF-38393, which by itself had
MK-801 (7)
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Figure 4. Eﬀects of the intra-medial prefrontal cortex (mPFC)
perfusion (line at foot of panels) of BAYr 3702 (BAY) (1 and
30 mM; BAY 1 and BAY 30, respectively) on the eﬄux of
(a) 5-HT and (b) glutamate in the mPFC elicited by MK-801
(1 mg/kg i.p., arrow). Data (mean¡S.E.M.) are expressed
as percentage changes of the four basal pre-drug values.
Number of animals given in parentheses. The control group
received an injection of saline (1 ml/kg i.p.). Groups given
saline and MK-801 are the same in all ﬁgures and are
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Figure 5. Eﬀects of the intra-medial prefrontal cortex (mPFC)
perfusion (line at foot of panels) of prazosin (Prz) (1 and
10 mM; Prz 1 and Prz 10, respectively) on the eﬄux of (a) 5-HT
and (b) glutamate in the mPFC elicited by MK-801 (1 mg/kg
i.p., arrow). Data (mean¡S.E.M.) are expressed as percentage
changes of the four basal pre-drug values. Number of animals
given in parentheses. The control group received an injection
of saline (1 ml/kg i.p.). Groups given saline and MK-801 are
the same in all ﬁgures and are depicted as dotted lines.
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no eﬀect on 5-HT and glutamate in saline-injected
animals, was unable to block the MK-801-induced in-
crease in dialysate 5-HT (Figure 6a). However, it pre-
vented the eﬀect of MK-801 on glutamate (F3,21=15.07,
p<0.0002 ; Figure 6b). Post-hoc comparisons showed
that both concentrations of SKF-38393 (1 and 10 mM)
signiﬁcantly abolished the increase in cortical gluta-
mate elicited by MK-801 (p<0.02, NK test). Although
it seemed that the concentration of 1 mM SKF-38393
was more eﬀective than that of 10 mM in blocking the
MK-801-induced increase of glutamate (Figure 6b),
this diﬀerence was not statistically signiﬁcant.
Discussion
In a previous study, we showed that the perfusion of
clozapine in the mPFC prevented the MK-801-induced
increase in glutamate and 5-HT, whereas haloperidol
blocked only the eﬀects on glutamate (Lo´pez-Gil et al.,
2007). In view of those results we proposed that
serotonergic transmission in the mPFC is regulated by
multiple monoamine receptors (for which clozapine
exhibits moderate to high aﬃnity), whereas gluta-
matergic transmission is regulated predominantly by
dopamine D2 receptor blockade (a key feature of anti-
psychotic action that prevails in typical antipsychotic
drugs such as haloperidol). The present work was
therefore aimed at testing the veracity of this prop-
osition, using selective agonists and antagonists for
monoamine receptors.
Eﬀects of dopaminergic drugs
In very good accordance with our hypothesis, two
diﬀerent dopamine D2 receptor antagonists, raclopride
and eticlopride, replicate the results of haloperidol, i.e.
both drugs prevented the MK-801-induced increase of
glutamate, but not that of 5-HT. Because onlyy5% of
projection neurons in layer V of the mPFC project to
the dorsal raphe nucleus (Gabbott et al., 2005), it is
conceivable that, under conditions of increased 5-HT
and glutamate transmission in the mPFC following
MK-801 administration, blockade of D2 receptors by
raclopride and eticlopride might be able to inhibit
cortical output (blockade of increased glutamate
eﬄux), although sparing cortico-raphe projections.
Tyrosine hydroxylase-positive terminals are in
apposition with GABA interneurons (Benes et al.,
2000 ; Sesack et al., 1998), and dopamine D2 receptors
are abundant in GABA interneurons of deep cortical
layers of the rat (Khan et al., 1998 ; Le Moine and
Gaspar, 1998; Vincent et al., 1995). Furthermore, dop-
amine exerts a tonic inhibitory eﬀect on fast-spiking
GABA cells that target the perisomatic domain of
pyramidal cells through D2 receptors (Gao et al., 2003;
Seamans et al., 2001). Therefore, an excessive release of
dopamine following MK-801 administration (Schmidt
and Fadayel, 1996) might lead to a further reduction
in GABAergic inhibition, which would result in an
impairment of the intrinsic cortical circuitry. In fact,
this has been postulated to occur in the schizophrenia
brain (Beasley et al., 2002 ; Benes, 1997 ; Egan and
Weinberger, 1997). Dopamine D2 antagonists would
relieve the inhibitory action of dopamine overﬂow on
GABA-containing neurons, thus promoting GABA
release and reducing cortical glutamatergic output
induced by MK-801. An important question that can
be raised here is whether dopamine D2 antagonists
would act on the same population of GABAergic
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Figure 6. Eﬀects of the intra-medial prefrontal cortex (mPFC)
perfusion (line at foot of panels) of SKF-38393 (1 and 10 mM;
SKF 1 and SKF 10, respectively) on the eﬄux of 5-HT (a) and
glutamate (b) in the mPFC elicited by MK-801 (1 mg/kg i.p. ;
arrow). Data (mean¡S.E.M.) are expressed as percentage
changes of the four basal pre-drug values. Number of animals
given in parentheses. The control group received an injection
of saline (1 ml/kg i.p.). Groups given saline and MK-801 are
the same in all ﬁgures and are depicted as dotted lines.
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subset of interneurons. Further research is needed to
answer this question.
The regulation of prefrontal function by dopamine
involves not only D2, but also D1 receptors. Our results
show that dopamine D1 agonism elicits comparable
eﬀects to those of dopamine D2 antagonists. It is
diﬃcult to reconcile the eﬀects of SKF-38393 with an
action on D1 receptors located on pyramidal neurons
(Bergson et al., 1995 ; Davidoﬀ and Benes, 1998)
because this receptor is excitatory. Since mPFC D1
receptors are also present on inhibitory GABA inter-
neurons (Davidoﬀ and Benes, 1998 ; Le Moine and
Gaspar, 1998), one possibility for the eﬀect of SKF-
38393 is activation of GABAergic inhibition, which
would block the increase in glutamate eﬄux induced
by MK-801. The lack of eﬀects of raclopride, eticlo-
pride and SKF-38393 on mPFC 5-HT suggests that
these two dopamine receptors could regulate distinct
inhibitory circuits, except those that control the pre-
frontal projection to the raphe nuclei, at least in the
conditions of the present study.
Altogether our results suggest that dopamine can
regulate the eﬄux of glutamate by means of an action
on GABAergic interneurons in the mPFC. Because
of the diﬀerent nature of dopamine D1 (excitatory)
vs. D2 (inhibitory) receptors, D2 antagonists and D1
agonists might end up with the same ﬁnal response,
i.e. to restore cortical GABA eﬄux in order to block
an excessive glutamatergic transmission following
MK-801 administration. Furthermore, our results are
also coincident with the proposal that D1 receptor
activation requires phasic dopamine release whereas
D2 receptors are continuously driven by basal, tonic
dopamine release (Grace, 1991).
Eﬀects of serotonergic and adrenergic drugs
In contrast to dopaminergic compounds, the selective
5-HT2A receptor antagonist, M100907, was able to
prevent the increase of 5-HT and glutamate evoked by
MK-801, which is in line with previous work using a
competitive NMDA antagonist (Ceglia et al., 2004).
This eﬀect can be accounted for by a reduction of the
increased excitability of prefrontal pyramidal neurons
(including those that project to the dorsal raphe
nucleus) produced by an exacerbated glutamatergic
transmission. In good accord with the present
work, previous studies from our laboratory have
demonstrated that M100907 also blocked the increased
serotonergic transmission caused by the intra-
mPFC perfusion of S-a-amino-3-hydroxy-5-methyl-4-
isoxazole-4-propionate (S-AMPA), 2,5-dimethoxy-4-
iodoamphetamine (DOI) and the a1-adrenoceptor
antagonist cirazoline (Amargo´s-Bosch et al., 2003,
2004), as well as thalamic disinhibition (Amargo´s-
Bosch et al., 2007). 5-HT2A receptors are predomi-
nantly localized to apical dendrites of pyramidal
neurons (Cornea-He´bert et al., 1999; Willins et al.,
1997), a cellular zone that receives inputs from diﬀer-
ent cortical layers, allowing cross-layer integration.
Consequently, 5-HT2A antagonists are in a unique
position to cancel the increased cortico-cortical trans-
mission that probably occurs after MK-801 adminis-
tration and the pharmacological conditions mentioned
above. Although there is evidence that 5-HT2A re-
ceptors are also present in cortical GABAergic inter-
neurons of the rat mPFC (Santana et al., 2004 ; Willins
et al., 1997), our results points to a predominant eﬀect
of M100907 on those receptors located in pyramidal
neurons following MK-801 administration.
The local perfusion of BAY x 3702 in the mPFC also
prevented the increased eﬄux of 5-HT and glutamate
following MK-801 administration with a potency
similar to that of M100907. Similarly, the 5-HT1A re-
ceptor agonist, 8-OH-DPAT, prevents the increase
in extracellular 5-HT and glutamate evoked by a
competitive NMDA antagonist (Calcagno et al., 2006).
The reduction of 5-HT is probably accounted for by a
decrease in the activity of pyramidal cells (Araneda
and Andrade, 1991 ; Ashby et al., 1994), which would
result in a reduction of a tonic excitatory input on the
dorsal raphe nucleus, thereby decreasing the activity
of 5-HT cells (Celada et al., 2001). Similarly to the
action of 5-HT2A receptor antagonists (see above),
previous work has also shown that 5-HT1A agonists
reverse the increased cortical 5-HT eﬄux induced by
intra-mPFC perfusion of S-AMPA, DOI and cirazoline
(Amargo´s-Bosch et al., 2003, 2004), as well as thalamic
disinhibition (Amargo´s-Bosch et al., 2007). In the
present study we show that BAY x 3702 also blocks
the eﬀects of MK-801 on glutamate. This suggests that
5-HT1A receptor activation in the mPFC potently at-
tenuates the action of agents that increase the activity
of pyramidal neurons, an eﬀect shared by several dif-
ferent treatments and involving the stimulation of
AMPA/kainate receptors in the mPFC (Katayama
et al., 2007 ; Lo´pez-Gil et al., 2007). Furthermore, the
pivotal localization of 5-HT1A receptors in the periso-
matic region of cortical pyramidal neurons of the rat
(Czyrak et al., 2003) might be the basis of the powerful
eﬀect of 5-HT1A receptor agonism. In addition, the high
level of expression of 5-HT2A and 5-HT1A receptors in
pyramidal cells labelled by vGluT1 (Santana et al.,
2004) together with the high co-localization of both
receptors in the mPFC (y80%; Amargo´s-Bosch et al.,
2004) provides further support for the neurochemical
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changes described. Although 5-HT2A and 5-HT1A
receptors are also expressed in cortical GABAergic
interneurons of the rat (Aznar et al., 2003; Santana
et al., 2004 ; Willins et al., 1997), they do not seem
to play a role in the control of cortical 5-HT and
glutamate in the conditions of the present work.
The local perfusion of the a1-adrenergic antagonist,
prazosin, in the mPFC was also able to prevent
the MK-801-induced increase in 5-HT and glutamate.
The eﬀect of prazosin probably involves the blockade
of a1-adrenoceptors located on pyramidal neurons,
including those in layer V that project to the dorsal
raphe nucleus, as previously observed for 5-HT2A
and 5-HT1A receptors. The mechanism of action of
prazosin is probably similar to that of M100907 in-
asmuch as both 5-HT2A and a1-adrenoceptors share
the same signal transduction mechanism and mediate
the excitatory actions of 5-HT and noradrenaline,
respectively, on pyramidal neurons of the mPFC
(Araneda and Andrade, 1991 ; Marek and Aghajanian,
1999). Moreover, they are localized to the same cortical
areas (Day et al., 1997 ; Domyancic and Morilak, 1997 ;
Pieribone et al., 1994). In line with the present work,
previous studies in our laboratory have demonstrated
that intra-mPFC perfusion of prazosin reversed the
increase of 5-HT elicited by the cortical application
of cirazoline, DOI and S-AMPA (Amargo´s-Bosch et al.,
2003), as well as thalamic disinhibition (Amargo´s-
Bosch et al., 2007).
Altogether these eﬀects need to be interpreted at
the cellular (pyramidal) and not at receptor level
because all these compounds do not interact directly
with each other’s receptors. It is therefore suggested
that antagonism at a1-adrenergic and 5-HT2A re-
ceptors, as well as agonism at 5-HT1A receptors are
able to prevent an excessive glutamatergic trans-
mission in the mPFC produced by diﬀerent treatments
and conditions.
Implications for antipsychotic action
The ﬁndings of the present and previous (Lo´pez-Gil
et al., 2007) work from our laboratory suggest that ex-
cessive glutamate transmission in the mPFC, second-
ary to a NMDA receptor blockade, may be associated
with some positive symptoms of schizophrenia, par-
ticularly those that are better responsive to dopamine
D2 receptor antagonism (a feature shared by most
antipsychotic drugs). In contrast, an impairment
of serotonergic pathways in the mPFC might rather
be related to negative symptoms and/or cognitive
deﬁcits, conditions for which clozapine and some
other atypical antipsychotics posses superior eﬃcacy.
It remains to be established, however, whether this
antiserotonergic eﬀect may confer the atypical proﬁle
of such drugs. There is a general consensus that
dopamine D2 blockers (typical neuroleptics) are less
eﬀective in treating negative/cognitive symptoms,
which, are better palliated by drugs with a strong
antagonism at 5-HT2A receptors and a weak blockade
of dopamine D2 receptors (see Meltzer, 2004 for re-
view). Thus, there is a clear need for targeting diﬀerent
transmitter receptors to achieve an eﬀective treatment
for schizophrenia. Our results indicate that 5-HT2A,
5-HT1A, dopamine D1 and a1-adrenergic receptors may
play an important role. Drugs showing 5-HT2A an-
tagonism and/or 5-HT1A agonism, such as clozapine,
increase dopamine eﬄux in the mPFC of rodents
(Assie´ et al., 2005 ; Ichikawa et al., 2001 ; Pehek and
Yamamoto, 1994 ; Rollema et al., 1997), an eﬀect that
appears to be dependent on the presence of intact
5-HT1A receptors (Bortolozzi et al., 2007 ; Dı´az-Mataix
et al., 2005). This selectivity on cortical dopamine
transmission together with a lesser occupancy of
limbic dopamine D2 receptors (Kapur et al., 1999)
appears to confer a better side-eﬀect proﬁle of
antipsychotics. However, selective 5-HT1A receptor
agonists do not appear to provide a distinct anti-
psychotic-like action, and their possible beneﬁt in the
clinic may rather be related to a lower appearance of
EPS (Millan, 2000).
The intra-mPFC administration of M100907, BAYr
3702 and prazosin prevents MK-801-induced increase
in 5-HT and glutamate, eﬀects that are comparable
to those obtained with clozapine (Lo´pez-Gil et al.,
2007). It is possible that this may relate to a better
treatment of most symptoms of schizophrenia. In fact,
preclinical studies have shown that antagonism at
5-HT2A receptors and agonism at 5-HT1A receptors can
ameliorate cognitive deﬁcits induced by NMDA re-
ceptor antagonists (Carli et al., 2006). Because each of
these receptor components do not confer antipsychotic
properties individually, it is conceivable that a com-
bined eﬀect is necessary to achieve this goal.
Dopamine D1 receptors are associated with sus-
tained activity of mPFC neurons and have been
postulated to be essential for working-memory per-
formance (see Goldman-Rakic et al., 2004 for review).
Clozapine may enhance dopamine D1 receptor-
mediated neurotransmission (Ahlenius, 1999 ; Oerther
and Ahlenius, 2000). Therefore, the pro-cognitive
action of clozapine could also result from its action on
dopamine D1 receptors or, alternatively, through
potentiation of NMDA transmission (see Millan, 2005
for review). If psychosis is modelled in animals by an
increased glutamatergic transmission in the mPFC
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(Adams andMoghaddam, 2001; Lo´pez-Gil et al., 2007;
Lorrain et al., 2003 ; Moghaddam et al., 1997), the
blockade of the eﬀect of MK-801 by SKF-38393
(present study) may argue in favour of the use of
dopamine D1 agonists in the treatment of the illness.
In summary, our results suggest that the com-
bination of blockade of dopamine D2, 5-HT2A and
a1-adrenergic receptors as well as agonism at dop-
amine D1 and 5-HT1A receptors in the mPFC may be
beneﬁcial in antipsychotic-like action. It appears that
dopamine D2 antagonists and dopamine D1 agonists
would activate cortical GABA inhibition. The lack
of eﬀect of dopaminergic compounds on the eﬄux of
5-HT implies that not all subtypes of GABAergic
interneurons are regulated in a similar way by dop-
amine (Seamans and Yang, 2004). Atypical antipsy-
chotic drugs might further act upon 5-HT2A, 5-HT1A
and a1-adrenoceptors present in pyramidal cells (in-
cluding those projecting to the dorsal raphe nucleus),
which would inhibit directly an excessive excitability
of these cells. This would contribute to the ﬁne-tuning
of discrete cortical circuits impaired in schizophrenia.
As we have suggested previously, it is possible that
an excessive glutamate transmission in the mPFC may
be related with positive symptoms of schizophrenia
that are generally alleviated by an antagonism at D2
receptors whereas an impaired serotonergic trans-
mission might rather be associated to negative symp-
toms and/or cognitive impairment.
The conclusions raised in the present study are
based on the analogies between the action of anti-
psychotic drugs and that of selective agonists and
antagonists for monoaminergic receptors. However, it
remains to be determined if there is any possible eﬀect
resulting from a combination of multiple interactions
among these receptors.
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